Andrew Crish has been named Chief Operating Officer by Greenbrook TMS Inc., with immediate effect. As the company’s chief operating officer, Andrew will oversee day-to-day operations and work closely with the executive leadership team to implement the company’s strategic growth plan.
Andrew has worked in a variety of fields for more than 20 years. Andrew held the position of Vice President of Operations at M2 Orthopedics from December 2021 until his departure from Greenbrook. Before that, from November 2018 to November 2021, he served as National Veterinary Associates’ Vice President of Operations. Andrew worked with DaVita Kidney Care in a number of positions before to joining National Veterinary Associates, including Division Vice President, Division Vice President of Hospital Service, Group Director of Hospital Services, and Director of Regional Operations. From September 2013 to November 2018, Andrew worked at DaVita Kidney Care. Prior to this, from April 2007 until December 2012, Andrew held positions as a Business Operations Manager, Director of Service, and Quality Assurance Leader at GE Healthcare. In addition, Andrew was employed at BearingPoint, Inc. as a Consultant from October 2006 to October 2007. Andrew was a Surface Warfare Officer, Facilities Manager, and Instructor in the US Navy from May 2000 to October 2006 before he entered the corporate world. From 1996 to 2000, Andrew studied economics for his Bachelor of Science degree at the United States Naval Academy. After that, Andrew continued his study and graduated with an MBA from Northwestern University’s Kellogg School of Management in 2008, with a focus on marketing, finance, management, and strategy.
Andrew has been in the business for more than 20 years and has a wide range of operational experience. The President and Chief Executive Officer, Bill Leonard, remarked, His enthusiasm for creating high-performing teams and optimizing operational efficiencies is a perfect fit with our vision for Greenbrook. They are overjoyed to have an executive with her level of skill and energy join our team.
With 130 treatment facilities run by the Company, Transcranial Magnetic Stimulation therapy and FDA-approved Spravato® are two of the most popular non-invasive treatments for Major Depressive Disorder and other mental health conditions offered by Greenbrook in the US. With TMS therapy, certain brain areas that are intimately linked to mood control get local electromagnetic stimulation. Adults with MDD who exhibit suicidal thoughts or behaviors and depressed symptoms who are resistant to treatment can be treated with Spravato®. Greenbrook has treated over 40,000 individuals with depression with over 1.3 million treatments.
